Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorVALLELUNGA, Annamaria
dc.contributor.authorIANNITTI, Tommaso
dc.contributor.authorCAPECE, Sabrina
dc.contributor.authorSOMMA, Gerardina
dc.contributor.authorRUSSILLO, Maria Claudia
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSAMIER FOUBERT, Alexandra
dc.contributor.authorLAURENS, Brice
dc.contributor.authorSIBON, Igor
hal.structure.identifierInstitut des Maladies Neurodégénératives [Bordeaux] [IMN]
dc.contributor.authorMEISSNER, Wassilios
IDREF: 113664761
dc.contributor.authorBARONE, Paolo
dc.contributor.authorPELLECCHIA, Maria Teresa
dc.date.accessioned2021-10-12T14:56:45Z
dc.date.available2021-10-12T14:56:45Z
dc.date.issued2021-07-26
dc.identifier.issn1663-4365en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/112756
dc.description.abstractEnParkinson's disease (PD) and Multiple System Atrophy (MSA) are progressive neurodegenerative diseases with overlap of symptoms in early stages of disease. No reliable biomarker exists and the diagnosis is mainly based on clinical features. Several studies suggest that miRNAs are involved in PD and MSA pathogenesis. Our goal was to study two serum circulating microRNAs (miR-96-5p and miR-339-5p) as novel biomarkers for the differential diagnosis between PD and MSA. Serum samples were obtained from 51 PD patients, 52 MSA patients and 56 healthy controls (HC). We measured levels of miRNAs using quantitative PCR and compared the levels of miR-96-5p and miR-339-5p among PD, MSA and HC groups using a one-way analysis of variance. Correlations between miRNA expression and clinical data were calculated using Pearson's rho test. We used the miRTarBase to detect miRNA targets and STRING to evaluate co-expression relationship among target genes. MiR-96-5p was significantly increased in MSA patients compared with HC (Fold change (fc): 3.6; p = 0.0001) while it was decreased in PD patients compared with HC (Fold change: 4; p = 0.0002). Higher miR-96-5P levels were directly related to longer disease duration in MSA patients. We observed a significant increase of miR-339-5p in MSA patients compared with PD patients (fc: 2.5; p = 0.00013). miR-339-5p was increased in MSA patients compared with HC (fc: 2.4; p = 0.002). We identified 32 target genes of miR-96-5p and miR-339-5p, some of which are involved in neurodegenerative diseases. The study of those miRNAs could be useful to identify non-invasive biomarkers for early differential diagnosis between PD and MSA.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enMicroRNAs
dc.subject.enBiomarkers
dc.subject.enParkinson's disease
dc.subject.enMultiple system atrophy
dc.subject.enMiR-96-5p
dc.subject.enMiR-339-5p
dc.title.enSerum miR-96-5P and miR-339-5P Are Potential Biomarkers for Multiple System Atrophy and Parkinson's Disease
dc.typeArticle de revueen_US
dc.identifier.doi10.3389/fnagi.2021.632891en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34381349en_US
bordeaux.journalFrontiers in Aging Neuroscienceen_US
bordeaux.page632891en_US
bordeaux.volume13en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamSEPIAen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03375369
hal.version1
hal.date.transferred2021-10-12T14:56:51Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Frontiers%20in%20Aging%20Neuroscience&rft.date=2021-07-26&rft.volume=13&rft.spage=632891&rft.epage=632891&rft.eissn=1663-4365&rft.issn=1663-4365&rft.au=VALLELUNGA,%20Annamaria&IANNITTI,%20Tommaso&CAPECE,%20Sabrina&SOMMA,%20Gerardina&RUSSILLO,%20Maria%20Claudia&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée